全文获取类型
收费全文 | 440580篇 |
免费 | 31194篇 |
国内免费 | 7425篇 |
专业分类
耳鼻咽喉 | 5559篇 |
儿科学 | 8876篇 |
妇产科学 | 10913篇 |
基础医学 | 60904篇 |
口腔科学 | 12858篇 |
临床医学 | 38517篇 |
内科学 | 87162篇 |
皮肤病学 | 9216篇 |
神经病学 | 30429篇 |
特种医学 | 16200篇 |
外国民族医学 | 123篇 |
外科学 | 66854篇 |
综合类 | 21397篇 |
现状与发展 | 18篇 |
一般理论 | 66篇 |
预防医学 | 21252篇 |
眼科学 | 11160篇 |
药学 | 37827篇 |
72篇 | |
中国医学 | 5758篇 |
肿瘤学 | 34038篇 |
出版年
2021年 | 5430篇 |
2020年 | 4179篇 |
2019年 | 5021篇 |
2018年 | 6804篇 |
2017年 | 5399篇 |
2016年 | 5477篇 |
2015年 | 7046篇 |
2014年 | 9505篇 |
2013年 | 10511篇 |
2012年 | 14627篇 |
2011年 | 15672篇 |
2010年 | 9353篇 |
2009年 | 8224篇 |
2008年 | 12747篇 |
2007年 | 13643篇 |
2006年 | 13691篇 |
2005年 | 12629篇 |
2004年 | 10936篇 |
2003年 | 10636篇 |
2002年 | 9933篇 |
2001年 | 29646篇 |
2000年 | 30280篇 |
1999年 | 25358篇 |
1998年 | 6167篇 |
1997年 | 5344篇 |
1996年 | 4641篇 |
1995年 | 4340篇 |
1994年 | 3853篇 |
1993年 | 3314篇 |
1992年 | 16555篇 |
1991年 | 15254篇 |
1990年 | 14542篇 |
1989年 | 14277篇 |
1988年 | 12848篇 |
1987年 | 12251篇 |
1986年 | 11278篇 |
1985年 | 10443篇 |
1984年 | 6986篇 |
1983年 | 5642篇 |
1982年 | 2731篇 |
1979年 | 5505篇 |
1978年 | 3345篇 |
1977年 | 2963篇 |
1975年 | 2636篇 |
1974年 | 3064篇 |
1973年 | 2863篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1970年 | 2509篇 |
1969年 | 2543篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
Kang Liu Gang Chen Shu-Yao Ren Yuan-Qiang Zhu Tian-Lei Yu Ping Tian Chen Li Yi-Bin Xi Zheng-Yu Wang Jian-Jun Ye Guo-Hong Han Hong Yin 《中国神经再生研究》2019,(5)
Hepatic myelopathy is a complication seen in patients with chronic liver failure with physiologic or iatrogenic portosystemic shunting. The main symptom is progressive lower limb dyskinesia. The role of the brain motor control center in hepatic myelopathy is unknown. This study aimed to investigate the gray matter changes in patients with hepatic myelopathy secondary to transjugular intrahepatic portosystemic shunt and to examine their clinical relevance. This was a cross-sectional study. Twenty-three liver failure patients with hepatic myelopathy(hepatic myelopathy group), 23 liver failure patients without hepatic myelopathy(non-hepatic myelopathy group) after transjugular intrahepatic portosystemic shunt, and 23 demographically matched healthy volunteers were enrolled from March 2014 to November 2016 at Xijing Hospital, Air Force Military Medical University(Fourth Military Medical University), China. High-resolution magnetization-prepared rapid gradient-echo brain imaging was acquired. Group differences in regional gray matter were assessed using voxel-based morphometry analysis. The relationship between aberrant gray matter and motor characteristics was investigated. Results demonstrated that compared with the non-hepatic myelopathy group, gray matter volume abnormalities were asymmetric, with decreased volume in the left insula(P = 0.003), left thalamus(P = 0.029), left superior frontal gyrus(P = 0.006), and right middle cingulate cortex(P = 0.021), and increased volume in the right caudate nucleus(P = 0.017), corrected with open-source software. The volume of the right caudate nucleus in the hepatic myelopathy group negatively correlated with the lower limb clinical rating of the Fugl-Meyer Assessment(r = –0.53, P = 0.01). Compared with healthy controls, patients with and without hepatic myelopathy exhibited overall increased gray matter volume in both thalami, and decreased gray matter volume in both putamen, as well as in the globus pallidus, cerebellum, and vermis. The gray matter abnormalities we found predominantly involved motor-related regions, and may be associated with motor dysfunction. An enlarged right caudate nucleus might help to predict weak lower limb motor performance in patients with preclinical hepatic myelopathy after transjugular intrahepatic portosystemic shunt. This study was approved by the Ethics Committee of Xijing Hospital, Air Force Military Medical University(Fourth Military Medical University), China(approval No. 20140227-6) on February 27, 2014. 相似文献
92.
Fahad A. Bashiri Hissah K. Al Abdulsalam Saeed M. Hassan Waleed A. Al Twaijri Fuad I. Almalki Amal Y. Kentab Muddathir H. Hamad Ali H. Alwadei Daniah A. Al-Showaeir Ikhlass S. Altweijri Haifa M. Aldabjan Moudi S. Aldegether Abdulrahman A. Albakr Wajda M. Alhothali Abdulrazag M. Ajlan Hamdy H. Hassan Mustafa A. Salih 《Neurosciences (Riyadh, Saudi Arabia)》2019,24(4):257
Objectives:To review the experience of 2 tertiary centers in Saudi Arabia with intracranial hypertension (IH) in the pediatric population.Methods:We retrospectively reviewed and analyzed pediatric patients diagnosed with IH from June 2002 to May 2017 in 2 institutes.Results:We identified 53 patients (30 females and 23 males) with a mean age of 7 years at the time of presentation. Among them, 41 patients were younger than 12 years, and 12 were older. Obese and overweight patients constituted 27.00% (n = 14) of all cases, 8 (66.7%) of whom were older than 12 years. The most common presenting feature was papilledema followed by headache. Vitamin D deficiency, which constituted the most common associated condition, was identified in 12 (22.6%) patients. Acetazolamide was the treatment option in 98.11% of patients, and only 5.7% underwent surgical interventions. The length of follow-up ranged from 6 months to 8 years.Conclusion:Intracranial hypertension is rare in children and commonly seen in overweight females older than 12 years similar to adults. Patients younger than 12 years tend to develop secondary IH. More studies are needed to characterize the clinical presentation and guide the management plan.Intracranial hypertension (IH) is rarely reported in children. It is characterized by increased intracranial pressure (ICP) without any evidence of underlying brain pathology, structural abnormalities, hydrocephalus, or any abnormal meningeal enhancement.1 The incidence of IH differs from region to region due to variations in the prevalence of obesity and other secondary causes. The annual incidence of IH in children is 0.9 per 100,000 in the United States,2 0.5 per 100,000 in Germany,3 0.6 per 100,000 in Nova Scotia and Prince Edward Island in Eastern Canada,4 and 1.2 per 100,000 in Croatia.5 A study carried out in Oman estimated the incidence of IH to be 1.9 per 100,000 in children below 15 years of age; with it being higher in female children.6 The present study aimed to review the clinical presentation, possible aetiological factors, diagnosis, management, and outcomes in children with IH in 2 tertiary institutes in Saudi Arabia. 相似文献
93.
94.
Xianxiu Ji Huikang Xie Ren Zhu Bin Chen Sen Jiang Jie Luo 《The Journal of international medical research》2021,49(2)
ObjectiveTo compare the baseline clinical characteristics between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer (NSCLC), and the correlations of these subtypes with the distribution of metastases.MethodsWe compared the clinical characteristics and imaging features of patients with ROS1-positive and ALK-positive NSCLC using statistical methods.ResultsData for 232 patients were analyzed. Compared with ALK-positive NSCLC, ROS1-positive NSCLC was more likely to occur in women (71% vs 53%), and primary lesions ≤3 cm were more common in patients with ROS1-positive compared with ALK-positive NSCLC (58% vs 37%). There was no significant difference in the distribution of metastases between the two groups. Subgroup analysis within the ROS1-positive group showed that, compared with primary lesions >3 cm, primary lesions ≤3 cm were more likely to present as peripheral tumors (72% vs 43%) and more likely to exhibit non-solid density (44% vs 4%).ConclusionsAlthough ROS1-positive and ALK-positive NSCLCs show similar clinical features, the differences may help clinicians to identify patients requiring further genotyping at initial diagnosis. 相似文献
95.
Jingjing Du Peiwen Zhang Jiang Luo Linyuan Shen Shunhua Zhang Hao Gu Jin He Linghui Wang Xue Zhao Mailing Gan Liu Yang Lili Niu Ye Zhao Qianzi Tang Guoqing Tang Dongmei Jiang Yanzhi Jiang Mingzhou Li Anan Jiang Long Jin Jideng Ma Surong Shuai Lin Bai Jinyong Wang Bo Zeng De Wu Xuewei Li Li Zhu 《Gut microbes》2021,13(1)
96.
Sirt5 is known to functionally regulate mitochondrial proteins by altering posttranslational modifications, including lysine desuccinylation. While roles for Sirt5 as either a tumor promoter or suppressor, or in chemoresistance, have been implicated in other cancers, the function of Sirt5 in cutaneous melanoma has not been well examined. Therefore, to determine whether Sirt5 is necessary for BrafV600E‐mediated melanoma formation and/or disease progression, we crossed a genetically engineered murine melanoma model (TyrCreERT2/+; BrafLSL‐V600E/+; Ptenflox/flox) to Sirt5?/? knockout animals. In addition, we tested for synergism with a selective BRAF (V600E) inhibitor in Sirt5?/? mouse melanoma cells. Taken together, this report demonstrates that, in these models, Sirt5 is dispensable for BrafV600E‐mediated cutaneous melanoma formation and growth in vivo, and does not improve sensitivity to a selective BRAF inhibitor. 相似文献
97.
P.V. Chernyshov A. Lallas L. Tomas‐Aragones M. Arenbergerova M. Samimi L. Manolache A. Svensson S.E. Marron F. Sampogna S. Spillekom‐vanKoulil A. Bewley A.M. Forsea G.B. Jemec J.C. Szepietowski M. Augustin A.Y. Finlay 《Journal of the European Academy of Dermatology and Venereology》2019,33(5):816-827
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health‐related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC‐specific, facial SC‐specific, NMSC‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma (FACT‐M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF‐36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer‐specific EORTC QLQ‐C30, especially in late stages of disease, and the melanoma‐specific FACT‐M and SC‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQoL instruments can be used to assess the impact of skin‐related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC. 相似文献
98.
99.
Daniel R. Edgcumbe Volker Thoma Davide Rivolta Michael A. Nitsche Cynthia H.Y. Fu 《Brain stimulation》2019,12(3):652-658